xalkori
pfizer europe ma eeig - crizotinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
ritalin uno hart hylki með breyttan losunarhraða 10 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 10 mg
ritalin uno hart hylki með breyttan losunarhraða 20 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg
ritalin uno hart hylki með breyttan losunarhraða 30 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg
ritalin uno hart hylki með breyttan losunarhraða 40 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 40 mg
ritalin uno hart hylki með breyttan losunarhraða 60 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 60 mg
metylfenidat actavis forðatafla 18 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 18 mg
metylfenidat actavis forðatafla 27 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 27 mg
metylfenidat actavis forðatafla 36 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 36 mg
metylfenidat actavis forðatafla 54 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 54 mg